Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0041 | 1 | 0.5 |
Schistosoma mansoni | cyclins | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclin B, putative | 0.0041 | 1 | 0.5 |
Echinococcus granulosus | cyclins | 0.0041 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 1 | 0.5 |
Echinococcus granulosus | cyclin B | 0.0041 | 1 | 0.5 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0041 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclins, putative | 0.0041 | 1 | 0.5 |
Giardia lamblia | G2/mitotic-specific cyclin B | 0.0041 | 1 | 0.5 |
Echinococcus granulosus | cyclin B3 1 | 0.0041 | 1 | 0.5 |
Leishmania major | cyclin | 0.0041 | 1 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0031 | 0 | 0.5 |
Echinococcus granulosus | G2:mitotic specific cyclin B3 | 0.0041 | 1 | 0.5 |
Loa Loa (eye worm) | cyclin domain-containing protein | 0.0041 | 1 | 0.5 |
Trypanosoma cruzi | cyclin 6, putative | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclin D, putative | 0.0041 | 1 | 0.5 |
Echinococcus granulosus | cyclins | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclins | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0041 | 1 | 0.5 |
Entamoeba histolytica | cyclin, putative | 0.0041 | 1 | 0.5 |
Trypanosoma brucei | mitotic cyclin 6 | 0.0041 | 1 | 0.5 |
Entamoeba histolytica | cyclin family protein | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclins | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclin B | 0.0041 | 1 | 0.5 |
Leishmania major | CYC2-like cyclin, putative,cyclin 6, putative | 0.0041 | 1 | 0.5 |
Giardia lamblia | Cyclin A | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclin B3 1 | 0.0041 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 1 | 0.5 |
Entamoeba histolytica | cyclin, putative | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | G2:mitotic specific cyclin B3 | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclins, putative | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclin A, putative | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclin B, putative | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclin B, putative | 0.0041 | 1 | 0.5 |
Echinococcus granulosus | cyclin b3 | 0.0041 | 1 | 0.5 |
Echinococcus granulosus | cyclins | 0.0041 | 1 | 0.5 |
Echinococcus granulosus | cyclins | 0.0041 | 1 | 0.5 |
Trypanosoma cruzi | cyclin, putative | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclins, putative | 0.0041 | 1 | 0.5 |
Echinococcus granulosus | cyclins | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclins | 0.0041 | 1 | 0.5 |
Trypanosoma cruzi | cyclin, putative | 0.0041 | 1 | 0.5 |
Trypanosoma cruzi | CYC2-like cyclin, putative | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclins | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclin D, putative | 0.0041 | 1 | 0.5 |
Entamoeba histolytica | cyclin family protein | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclin B3, putative | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclin B, putative | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclins | 0.0041 | 1 | 0.5 |
Schistosoma mansoni | cyclin B | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclins | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclin B, putative | 0.0041 | 1 | 0.5 |
Onchocerca volvulus | 0.0041 | 1 | 0.5 | |
Schistosoma mansoni | cyclin B3 | 0.0041 | 1 | 0.5 |
Plasmodium falciparum | cyclin | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclins, putative | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclin b3 | 0.0041 | 1 | 0.5 |
Trichomonas vaginalis | cyclins, putative | 0.0041 | 1 | 0.5 |
Echinococcus multilocularis | cyclins | 0.0041 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.